Non-Hodgkin lymphoma

The National Institute for Health and Care Excellence (NICE) has recommended zanubrutinib (Brukinsa) as an option for treating some people…

Ibrutinib, a drug used to treat Waldenstrom’s macroglobulinaemia, is not being recommended by the National Institute for Health and Care Excellence in England

Three new treatment options made available for cancer patients in Scotland.

The three latest SMC decisions will provide new treatment options for some adults with non small cell lung cancer, multiple myeloma and a rare type of lymphoma.

Lymphoma patients in England are among the first in the world to be offered new CAR T cell therapy.

The National Institute for Health and Care Excellence has recommended a new combination therapy for adults with an aggressive type of non-Hodgkin lymphoma.

The National Institute for Health and Care Excellence (NICE) has approved the drug brentuximab vedotin on the NHS in England.

New clinical trial results show that adding rituximab to standard chemotherapy could improve survival for some children with non-Hodgkin lymphoma.

A new combination therapy for adults with an aggressive type of non-Hodgkin lymphoma has not been recommended for NHS use in England. 

New ‘chemotherapy-free’ treatment for follicular lymphoma approved for NHS use in England.